CN102711709A - Devices, methods, and composition for controlling infections - Google Patents
Devices, methods, and composition for controlling infections Download PDFInfo
- Publication number
- CN102711709A CN102711709A CN201080048369XA CN201080048369A CN102711709A CN 102711709 A CN102711709 A CN 102711709A CN 201080048369X A CN201080048369X A CN 201080048369XA CN 201080048369 A CN201080048369 A CN 201080048369A CN 102711709 A CN102711709 A CN 102711709A
- Authority
- CN
- China
- Prior art keywords
- chlorhexidine
- wound
- solution
- container
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Abstract
The subject invention provides novel and highly effective methods and devices for convenient and effective wound irrigation.
Description
The cross reference of related application
The application requires the rights and interests of the U.S. Provisional Application serial number 61/254,906 of submission on October 26th, 2009, and this application is whole introduces this paper as a reference.
Background of invention
Processing and treatment to wound have three main purposes: (1) prevention infection, preserve and/or restore funcitons (2), and preserve and/or the recovery pleasing aesthetic appearance (3).These purposes the most important thing is prevention infection.The success of prevention infection directly influences the recovery from illness process and influences function and degree that pleasing aesthetic appearance is preserved and/or recovered.Yet up to now, wound douche does not also have the direct union of using with the medicine that can alleviate infection or otherwise promote to fully recover.
Be known that the number of bacteria that exists in region of interest is a whether contagious crucial determiner of wound.Experimental evidence shows that the critical level of antibacterial is about every gram tissue 10
5Individual organism.Be lower than this level, wound can be fully recovered usually; Surpass 10 at every gram tissue
5The level of individual antibacterial, wound are infected usually.All traumatic wounds are receiving pollution (Dire when handle the medical space; Daniel I. [1990] " comparison (A comparison ofWound Irrigation Solutions Used in the Emergency Department) of the wound douche solution that uses in emergency department, " Annalsof Emergency Medicine 19 (6): 704-708).Dirty wound or in six hours untreated wound might be higher than the germ contamination of critical level.Reduce in the wound with wound around number of bacteria be to avoid infection and promote the key of wound recovery from illness.
Methicillin-resistant staphylococcus aureus (MRSA) infects and is caused by staphylococcus aureus (staphylococcus aureus) (being commonly referred to " staphylococcus " (staph.)).Before the many decades, in hospital, occurred being usually used in handling their the drug-fast aureus strains of broad ectrum antibiotic.These antibiotic comprise methicillin and other more common antibiotic such as oxazacillin, penicillin and amoxicillin.So-called methicillin-resistant staphylococcus aureus (MRSA) is to except that one of drug-fast first batch of pathogenic bacteria of all medicines the potent drug thing.
Staphylococcus is normally harmless, only if they get into health through otch or other wound.Old age adult and ill or have the immune philtrum that weakens, common staphy lococcus infection can cause serious disease.Staphy lococcus infection (comprising MRSA) the most often betides the philtrum at hospital and health care institution such as sanatorium and dialysis center, and these people have the immune system that weakens.
In the nineties in 20th century, one type of MRSA begins to appear at widely in the community.Nowadays, the staphylococcus that is called the sort of form of relevant MRSA of community or CA-MRSA is the reason of the pneumonia of many serious skins and soft tissue infection and severe form.When appropriately not handling, it can be fatal that MRSA infects.
MRSA infects in the U.S. and global bamboo telegraph.According to CDC (CDC), the ratio that the combating microorganisms agent has chemical sproof infection is increasing always.1974, MRSA infected and accounts for 2 percent of staphy lococcus infection sum; Nineteen ninety-five, it is 22%; In 2004, it was near 63%.In addition, recent research shows that the crowd of 30-50% carries MRSA group always on their health, and this has promoted the propagation of infecting.
Although think that traditionally MRSA is hospital's infections relating, have also in the U.S. that CA-MRSA's is popular.MRSA in the community infects and shows as skin infection, for example pimple and furuncle usually.These CA-MRSA infect and can occur in the healthy subjects in addition, and usually occur in and share equipment or personal belongings, comprise between the athlete of towel and razor.In fact, from 2000 so far, several times have been reported the outburst of the CA-MRSA that influences middle school team.This popular between the athlete encouraged by the following fact: MRSA in warm, moist zone such as gymnasium and gymnasium dressing cubicle very rapidly grow.Because PI MRSA, common otch faces significant threat with scratch like those that in football and basketball, very frequently occur now.
Vancomycin is still one of effective only a few antibiotic of antagonism MRSA hospital strain infection, although this medicine is all effective no longer in each case.Multiple medications remains valid and resists CA-MRSA, but CA-MRSA is the antibacterial of tachytelic evolution, and it becomes the most of antibiotics drug resistance possibly also be matter of time.
Chlorhexidine is chemical antibacterial, its antagonism gram-positive microorganism and gram-negative micro-organism.It is a bacteriostatic, hinders bacterial growth, and is germ-resistant, can kill bacteria.It is usually as the active component in the collutory that is designed to kill dental plaque and other oral cavity bacterium.Chlorhexidine also has non-dental applications.For example, it is cleaned before as art and is used for general skin clean as skin preparation before the art.
Chlorhexidine uses separately with the form of acetate, gluconate or hydrochlorate usually or unites use with other antibacterial such as cetab.
The invention summary
The invention provides and be used for sending effectively one or more medicines or other active component to patient's target site to alleviate, to stop and/or to treat new and high-efficiency method, device and the compositions that infects.
The instance that can be applied to patient's material according to the present invention includes but not limited to antibacterial agent, antiviral agent, antifungal, chemotherapeutics, topical antiseptic, anesthetis, oxygenate (oxygenated) fluid and/or material, antibiotic, diagnostic agent, Homeopathic agent and over-the-counter drug/material.In preferred embodiments, activating agent is a chlorhexidine gluconate, and preferred concentration is lower than 1.0%, more preferably less than 0.1%, most preferably is lower than 0.05% or lower.
In an embodiment; The invention provides the storage capsule (reservoir housing) that contains rinse solution with one or more activating agents; Wherein storage capsule has connected exhaust apparatus; Said exhaust apparatus has one or more openings, and the solution of enough volumes can pass said opening to target site under the suitable pressure of effectively sending solution (comprising activating agent).
Detailed Description Of The Invention
The invention provides new, easily, inexpensive and effective medicine delivery technique, in an embodiment, the device that its utilization has storage capsule and exhaust apparatus is used for bioactive agent delivery is delivered to target site.The present invention also provides compositions and has used this device and method for compositions.
Material of the present invention and method make it possible to convenient and the fluid administration that easily will contain medical substances for example in for example wound.In an embodiment, wound is an operative site.
" activating agent " used herein is meant chemical compound or other entity with treatment and/or diagnostic function.This function can be directly, for example promotes tissue repair or kill cancer cell, perhaps can finally cause expecting useful result's physiological responses but indirect through causing.
In an embodiment, will comprise 0.05% or lower (or even be lower than 0.04%, or even be lower than 0.03%) sterilized water (non-saline) solution of chlorhexidine is applied to the wound of human skin.Preferably, then in 5 minutes (preferably in 1-3 minute) with not containing the Sterile Saline or the water liquid wash wound of chlorhexidine.
In another embodiment, solution is applied to operative site.
In specific embodiment, chlorhexidine gluconate used according to the invention has following chemical constitution:
In preferred embodiments, about 15-25mg chlorhexidine gluconate is applied to wound.In an embodiment, wound is scratch or laceration, and before reparation/closure, uses this solution.
The pH of solution is preferably neutrality or faintly acid.PH is preferably 5.0 to 7.5.PH more preferably 5.5 to 7.0.In an embodiment, under the situation that does not have foaming agent (sudsing agent), use chlorhexidine.
In certain embodiments, compositions does not contain any composition that promotes growth of microorganism.Preferably, compositions does not comprise denseness and makes up agent, and this term is openly applied for using in 2007/0184114 in the U.S., the whole this paper that introduces of this application.
In specific embodiment, the solution that will contain CHG is applied to the open operation wound.Can be under pressure or under pressure, do not use this solution.In an embodiment, solution is not used through jet douche (jet lavage).In another embodiment, fluid is not used under pressure.Preferably, the patient is the people.The patient can also be for example Canis familiaris L., horse, cat, pig or cattle.
Preferably, after using CHG solution, in 1,5 or 10 minute with this position of brine wash.
In the environment of operating room, the solution that contains CHG is preferably in sterile chamber.Container can be sterilized through for example radiation.
In an embodiment, can in little ampoule, CHG be provided, so that the content of ampoule bottle be introduced in the water of standard-sized bottle for example or joins in IV bag or the circuit CHG solution that has aforesaid CHG concentration with generation.
Solution of the present invention can also be provided in the IV bag.
In other embodiments, the invention provides antimicrobial lotion, cream, sponginum and suppository.These embodiments preferably contain CHG as active component.These embodiments directly offer the position that needs antimicrobial acivity with the CHG of concentration described herein.
The aqueous solution that contains CHG can have other component, comprises material (for example helping the material of degradation biological tunicle) and other therapeutic and the non-therapeutic chemical compound of for example pH regulator agent, buffer agent, local anesthetic, the recovery from illness of promotion wound.In an embodiment, the aqueous solution of compositions " basically by " CHG " is formed ", this means that solution does not contain the active substance that other changes the ability of solution control bacterial growth in fact.
In preferred embodiments,, application uses the normal saline washing wound after containing the solution of CHG.Not only CHG is rinsed out with normal saline washing, and saline is at the CHG that chemically neutralized, stops thus or alleviate edema.Preferably after using CHG, use about 30 seconds to about 5 minutes flushing.Flushing can be about 100ml to 1000ml saline, uses about 5 seconds to about 1 minute usually.
In preferred embodiments, when comparing with undressed wound or with the wound of saline that does not contain chlorhexidine or water flushing, the application of rinse solution of the present invention causes the bacterial population of site of injury to reduce.Advantageously, the effective control infection and do not cause tissue injury of the use of CHG of the present invention.
Advantageously, rinse solution of the present invention can be effectively to infection, even when existing organic substance also like this when (comprising blood, tissue and/or dirt and chip).Certainly, this type of material is present in all skin traumas.
Except killing bacteria; Preparation of the present invention can also make some antibacterial, comprise that for example escherichia coli (E.coli) and aerogenesis Cray Bai Shi bacillus (Klebsiella aerogenes) " formerization of preventing or cure a disease " (depathogenize) make these antibacterials can not cause infection.
Advantageously, the compositions and methods of the invention even when having biofilm, also can be used for treating effectively wound.
Delivery method of the present invention can be sent the associating use with the activating agent that carries out through the numerous approach shown in the table 1.Interestedly especially be: approach in approach (intra-operative), flushing approach, nose approach, the auditory meatus in approach, the thoracic cavity in approach, intracranial approach, the damage in skin approach, the abdomen, as mouth intestinal prepared product, be used for gastric lavage, as a detergent, periodontal approach, rectum approach, soft tissue approach, subcutaneous route and vaginal approach.Compositions of the present invention also can be used for controlling acne and other skin infection, comprises that foot and scalp infect.In an embodiment, chlorhexidine compositions of the present invention is used to treat abscess.Preferably, adopt the exhaust openings that for example has prolongation solution to be applied to abscess dearly with the device that helps effectively to use.
Under the environment of the best, use drug delivery device of the present invention and method through well-trained medical skill personnel; Yet because device of the present invention is simple and convenient, they can be used for greatly improving the effectiveness that medicine is sent, and need not consider to carry out the operator's of flushing the level of training.
The activating agent of sending
The instance that can be applied to patient's material according to the present invention includes but not limited to antibacterial agent, antiviral agent, antifungal, chemotherapeutics, topical antiseptic, anesthetis, oxygenate fluid and/or material, antibiotic, diagnostic agent, Homeopathic agent and over-the-counter drug/material.
The target site that can use active component according to the present invention includes but not limited to wound and operative site.Operative site can comprise for example joint replacement position, abdominal operation position, brain operative site and/or mouth/periodontal surgery position.In various situation, be uniqueness and very favorable with the ability that active component is delivered to specific part with suitable dosage.
The solution that carries activating agent can be for example water, saline or balanced salt solution.This solution is preferably aseptic.In the situation of CHG, solution is water preferably.Can be through known sterilization technology, comprise boil, autoclaving, gaseous sterilization, irradiation etc. individually or this device is sterilized together with storage capsule.
It is particularly advantageous using chlorhexidine, because it is broad-spectrum, is bonded to skin (so that residual activity to be provided), fast-acting, and when using according to the present invention, is nontoxic.
Chlorhexidine is the chemical antibacterial that can be used for resisting gram-positive and gram-negative micro-organism.It is antibacterial and antibacterial.The antibacterial that in the traumatic infection and/or the phlegmonous cause of disease of Secondary cases, relates to various kinds.Sometimes these infection can cause damaging profile, forfeiture limbs, postpone rehabilitation and/or death.The therapeutical effect of rinse solution of the present invention is with those character antagonism relevant with flushing process self microorganism that relates to be arranged in the pathology of these infection usually through its antibacterial properties.Microbial load in the control wound is to make minimize infection and so minimizing and/or prophylactic key factor.
Activity profile
Chlorhexidine has the activity of aerobic and anaerobic Gram-positive of antagonism and gram negative bacteria.This medicine also has antagonism chlamydia trachomatis (Chlamydia trachomatis), some fungus and activity that some is viral.
Aerobe
Chlorhexidine is highly effective to various Gram-positive aerobes, and said aerobe comprises Streptococcus mutans (Streptococcus mutans), streptococcus pyogenes (S.pyogenes) (A crowd's beta hemolytic streptococcus), streptococcus salivarius (S.salivarius) and Streptococcus sanguis (S.sanguis).Chlorhexidine has the activity of antagonism staphylococcus aureus (Staphylococcus aureus), staphylococcus epidermidis (S.epidermidis), staphylococcus haemolyticus (S.haemolyticus), staphylococcus hominis (S.hominis), imitation staphylococcus (S.simulans).This medicine has the activity of antagonism percentage of methicillin-resistant (ORSA) and the responsive staphylococcus of oxazacillin (being also referred to as methicillin resistance (MRSA) or methicillin-sensitivity staphylococcus).Chlorhexidine has the antagonism enterococcus, comprises the activity of enterococcus faecalis (E.faecalis) and enterococcus faecalis (E.faecium), and has the activity of responsive to anti-vancocin to drug resistance of vancomycin bacterial strain.
Anaerobic bacteria
Chlorhexidine has the activity of some anaerobic bacterias of antagonism.This medicine has the activity of some bacterial strains of antagonism Bacteroides (Bacteroides), propionibacterium (Propionibacterium), clostridium difficile (Clostridiumdifficile) and Selenomonas (Selenomonas), but lower to Wei Rong Shi Coccus (Veillonella) activity.
Fungus
Chlorhexidine has anti-candida albicans (Candida albicans); Candida dubliniensis (C.dubliniensis); Candida glabrata (C.glabrata) (being called torulopsis glabrata (Torulopsisglabrata) in the past); Candida guilliermondi (C.guillermondii); Candida kefyr (C.kefyr) (being called candida pseudotropicalis (C.pseudotropicalis) in the past); Candida krusei (C.krusei); Some activity of Candida lusitaniae (C.lusitaniae) and Oidium tropicale (C.tropicalis) (being called Candida parapsilosis (C.parapsilosis) in the past).Chlorhexidine also has some activity to anti-dermatophyte, and said dermatophytes comprises acrothesium floccosum (Epidermophyton floccosum), microsporum gypseum (Microsporum gypseum), the little spore bacterium of dog (M.canis) and Trichophyton mentagrophytes (Trichophytonmentagrophytes).
Virus
Chlorhexidine shows to have the antiviral activity that antagonism has lipid composition or has the virus of peplos on its shell, and said virus for example is cytomegalovirus (CMV), human immunodeficiency virus (HIV), herpes simplex types 1 virus (HSV-1) and herpes simplex types 2 virus (HSV-2), influenza virus, parainfluenza virus and smallpox virus.
Method and formulation
Advantageously, because method of the present invention can be used for active component accurately and effectively is delivered to patient's target site, therefore in certain embodiments, can use the active component that reduces concentration.Therefore, in an embodiment of the present invention, the low concentration solution that can use chlorhexidine for example reduces the infection at wound, operative site or other tissue openings place effectively.In preferred embodiments, chlorhexidine is lower than 4%.In a more preferred embodiment, chlorhexidine is lower than 2% or be lower than 1% or even be lower than 0.1%.In an embodiment, chlorhexidine is 0.05%.In other embodiments, chlorhexidine is 0.02% to 0.05%.What this paper specifically enumerated is the application of chlorhexidine gluconate.
As stated, in an embodiment of the present invention, use device of the present invention activating agent such as antimicrobial are delivered to target site such as wound.Behind administering active agents, then can be for example with this position of normal saline washing to remove excessive activating agent at least arbitrarily.Preferably, this flushing occurs in 5 minutes that use chlorhexidine.More preferably, this flushing occurs in 1 to 3 minute that uses chlorhexidine.Like this, can reduce or eliminate any genotoxic potential relevant with activating agent.In the situation of chlorhexidine gluconate, removed the excessive for example proteinic chlorhexidine of skin that is not bonded to the flush fluid flushing.
In another embodiment, can use apparatus and method of the present invention and use diagnostic agent.Diagnostic agent can for example be and the bonded antibody of target biomolecule, protein or polynucleotide.Can use technology well known by persons skilled in the art then makes this type of combination arbitrarily visual.These technology comprise for example use fluorogen maybe can be through bore hole or other labelling that manifests through suitable detecting instrument.Diagnosis Application of the present invention comprises bacterial detection, virus, parasite and other pathogen.Can also use diagnostic method of the present invention makes cancerous cell visual.
In another embodiment, these apparatus and method can be used for somatomedin and/or protease inhibitor are delivered to target site.Can for example promote that this type of somatomedin and/or the protease inhibitor of wound recovery from illness are well known to a person skilled in the art.
In another embodiment, method of the present invention can be used for oxygenate water and/or " fortified water " (enhanced water) are delivered to target site.Fortified water can be those (all whole this paper of introducing of this application and list of references as a reference) of for example in U.S. Patent No. application 20050191364 and its list of references of quoting, putting down in writing.The method of the present invention that is used for effectively sending this type oxygenate or fortified water can be used for promoting the tissue recovery from illness and alleviates infection.
In another embodiment, apparatus and method of the present invention can be used for antimicrobial peptide (AMP) is delivered to target site effectively.AMP is well known in the art.Antimicrobial peptide mainly is the little polypeptide that suppresses growth of microorganism.As autarcetic effector, antimicrobial polypeptide directly kills broad-spectrum antibacterial, fungus and virus.In addition, these peptides are also regulated local inflammation reaction and activate mechanism cell and acquired immunity.Cathepsin inhibin (cathelicidins) and alexin comprise the major families of AMP in the skin, although other leucotaxine such as protease inhibitor, chemotactic factor and neuropeptide also show antimicrobial acivity.For example referring to Braff, people such as M, (2005) " through skin defense mechanism (Cutaneous Defense Mechanisms byAntimicrobial Peptides) of antimicrobial peptide ", J Invest Dermatol, 125:9-13.
Drug delivery device
Device of the present invention can for example be openly to apply for the device shown in the US-2008-0159963-A1 like the U.S., and this application is whole introduces this paper as a reference.The storage storehouse can for example be 100ml to 1000ml.
In an embodiment; The invention provides the storage capsule that contains the solution that comprises one or more activating agents; Wherein storage capsule has connected exhaust apparatus; Said exhaust apparatus has one or more openings, and the solution of enough volumes can pass said opening to target site under the suitable pressure of effectively sending solution (comprising activating agent).
Storage capsule and content can be stored in the gnotobasis, for example in the aseptic bag that faces with front opening.Can make storage capsule point to site of injury, push or compress and make solution discharge or discharge with expecting pressure, thereby wash wound effectively to remove pollutant or chip and active agent delivery towards anticipated orientation.
Exhaust apparatus can separate with storage capsule to be packed.Exhaust apparatus is packed in gnotobasis.In an embodiment, in aseptic dish, drug delivery device is provided.According to the present invention, except drug delivery device of the present invention, the wound charging tray contains also that for example other is convenient to be used for handling the device of wound.The device that can be included in the expection in the wound charging tray includes but not limited to needle holder (promptly 5 " base level smooth type (floor-grade smooth)); Shears (promptly 4.5 " the straight iris scissors of base level); Mosquito forceps (promptly 5 " the curved mosquito forceps of base level); Tweezers (be the base level tissue clamps, have 1 * 2 tooth); Cup (i.e. 2 ounces of medicine glasses); Syringe (being 10cc luer lock head (Luer Lock) syringe); Pin (promptly No. 25 * 5/8 " pin; No. 27 * 1.5 " pin; No. 18 * 1.5 " pin); Dressing (being gauze dressing); Drop cloth (being multi-thread drop cloth with holes); And towel (being the hygroscopicity towel).
It should be noted that the known at present little microgranule (for example antibacterial) of the surface area microgranule (for example dirt, sand or plant) bigger than the removing surface area of from wound, removing needs bigger power.The minimum recommended volume of rinse solution is different, but for middle-sized the wound of potentially contaminated being arranged, for example for 3 to 6 centimeter length and the dark laceration below 2 centimetres, should using at least 200 to 500ml or more rinse solution.For wound bigger or severe contamination, possibly need bigger volume, be approximately 1 to 2 liter.Till that flushing should continue is visible at least to all, the loose granule material is eliminated.
Hereinafter is the embodiment that sets forth the method that is used for embodiment of the present invention.These embodiment should not be construed as limitation of the present invention.
Embodiment 1-purging method
When the patient when other health care professional of doctor or this area reveals its wound, the injured degree of this medical personnel's assess comprises all other life-threatening injuries.These life-threatening injuries are carried out proper process work and write down case history.All wounds are covered so that further minimize contamination, begin until the repair process of reality.
For the wound inspection, suppose that the medical matters professional has carried out detailed assessment to the degree of tissue injury, includes but not limited to: the consideration of anatomy area; Wound depth; Type of injury, like: comminuted injury, stab, bite, wound, the incised wound of sharp objects, or the like.In the inspection also with comprise definite pollution type, from total body pollution of hurting present time, wound and with increase relevant other medical factor (for example diabetics, AIDS patient and patients undergoing chemotherapy) of the incidence of infection.
Before coming into effect the wound clean method,, can carry out surface, part or general anesthesia to wound and surrounding tissue thereof according to medical personnel's selection.Perhaps, can use apparatus and method of the present invention and send anesthetis.
Pressure manual or that machinery produces is applied on the storage capsule, discharges through the nozzle of exhaust apparatus so that contain the rinse solution of activating agent.Wash wound by this way, all be eliminated up to all visible pollutant.Should use the possible contaminated wounds of the rinse solution flushing arbitrary dimension of minimum 200-300 milliliter.Severe contamination or big wound possibly need 2-3 to rise rinse solution.
After the preliminary flushing wound, the reply wound is checked.Need look round the bottom of wound, to confirm not have visible foreign body or pollutant residual.If find foreign body or pollutant, should repeat flushing process after the check.This continues several times possibly.
In case flushing is accomplished, promptly do not have visible pollutant residual after, will repair damaged tissues with received standard mode.
The same with the flushing of operative site, skin trauma such as incised wound, scratch, stab, the flushing of scratch etc. is particularly suitable for flushing of the present invention.
Embodiment 2-route of administration
Table 1 provides the tabulation of operable various route of administration according to the present invention.
Be to be understood that; Embodiment as herein described and embodiment only are in order to explain the present invention, various accommodations or change and under it inspires, will be prompted to those skilled in the art and be easy to be included in the application's aim and the scope and in the scope of appended claims.
Claims (20)
1. contain the sterile chamber that is included in aseptic aqueous solution wherein, said solution comprises 0.05% or the chlorhexidine of lower concentration.
2. according to the container of claim 1, it contains the said solution of 100ml to 1000ml.
3. according to the container of claim 1, wherein said container also comprises back shelves shell (backsplashshield).
4. according to the container of claim 1, wherein chlorhexidine exists with 0.05% concentration.
5. according to the container of claim 1, wherein chlorhexidine is the form of chlorhexidine gluconate.
6. wash the method for wound, said method comprises that the content with the container of claim 1 is applied to wound.
7. the method for claim 6, wherein said device also comprise back shelves shell.
8. the method for claim 6, it also is included in 5 minutes with the solution flushing wound that does not contain chlorhexidine.
9. the method for claim 6 is used for handler's wound.
10. the method for claim 6, wherein the concentration of chlorhexidine is 0.05%.
11. the method for claim 6 is used for surgical site irrigation.
12. the method for claim 11, wherein type of surgery is selected from orthopaedic surgery, cardiac operation, cerebral surgery operation and abdominal surgery.
13. the method for claim 6 is used to treat MRSA and infects.
14. the method for claim 13, the wherein known MRSA of existence before using said solution.
15. the method for claim 6 is used to treat abscess.
16. contain the ampoule of chlorhexidine, wherein the concentration of chlorhexidine makes and to be lower than 1.0% chlorhexidine concentration when the content of ampoule gained solution when being in water that 250ml to 5 rises the known volume of scope and mixing has.
17. with 0.05% or the chlorhexidine of lower concentration be delivered to cream, lotion, sponginum, the suppository of infection site or encapsulate the indwelling medication device.
18. the compositions of claim 17 is used for the purposes of control infection.
19. medicine box comprises the container of claim 1 and the saline of a container.
20. according to the medicine box of claim 19, it is aseptic.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25490609P | 2009-10-26 | 2009-10-26 | |
| US61/254,906 | 2009-10-26 | ||
| PCT/US2010/053884 WO2011056486A2 (en) | 2009-10-26 | 2010-10-24 | Devices, methods, and composition for controlling infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102711709A true CN102711709A (en) | 2012-10-03 |
Family
ID=43970646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080048369XA Pending CN102711709A (en) | 2009-10-26 | 2010-10-24 | Devices, methods, and composition for controlling infections |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2493442A4 (en) |
| JP (1) | JP2013508457A (en) |
| CN (1) | CN102711709A (en) |
| CA (1) | CA2778081A1 (en) |
| WO (1) | WO2011056486A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105979940A (en) * | 2013-12-12 | 2016-09-28 | 创新技术股份有限公司 | Materials and methods for controlling infections |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5872430B2 (en) * | 2012-09-20 | 2016-03-01 | 日本電子照射サービス株式会社 | Chlorhexidine gluconate formulation, disinfection kit and sterilization method |
| US10016375B2 (en) | 2013-12-12 | 2018-07-10 | Paul J. Rucinski | Materials and methods for controlling infections |
| US20160038442A1 (en) * | 2014-08-08 | 2016-02-11 | Innovation Technologies, Inc. | Materials and methods for controlling infections with negative pressure wound therapy |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231606A (en) * | 1996-08-01 | 1999-10-13 | 史密丝克莱恩比彻姆药品(私人)有限公司 | Composition comprising mupirocin and chlorhexidine |
| US20040185028A1 (en) * | 2003-03-19 | 2004-09-23 | Zhenze Hu | Antimicrobial compositions containing ethanolamine buffer and biguanide disinfectant |
| US20050124946A1 (en) * | 2003-12-05 | 2005-06-09 | Sergio Landau | Wound irrigation apparatus and method |
| US20060051385A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| CN1871039A (en) * | 2003-09-22 | 2006-11-29 | 技术革新公司 | Wound irrigation device and method |
| US20070173773A1 (en) * | 2006-01-23 | 2007-07-26 | Keith Stamler | Wound irrigation splashback shield |
| WO2008077114A2 (en) * | 2006-12-19 | 2008-06-26 | Innovation Technologies, Inc. | Devices and methods for delivering active agents to target sites |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017516A (en) * | 1997-10-31 | 2000-01-25 | Lekar Pharma Limited | Pharmaceutical dental formulation for topical application of metronidazole benzoate and chlorhexidine gluconate |
| US20050191247A1 (en) * | 2004-03-01 | 2005-09-01 | David Drake | Chlorhexidine compositions |
| JP2006117587A (en) * | 2004-10-22 | 2006-05-11 | Dainippon Sumitomo Pharma Co Ltd | Germicidal disinfectant composition |
| US20070036846A1 (en) * | 2005-08-15 | 2007-02-15 | Tsang Wing W M | Wound dressing and method of manufacture thereof |
-
2010
- 2010-10-24 CA CA2778081A patent/CA2778081A1/en not_active Abandoned
- 2010-10-24 CN CN201080048369XA patent/CN102711709A/en active Pending
- 2010-10-24 WO PCT/US2010/053884 patent/WO2011056486A2/en active Application Filing
- 2010-10-24 EP EP10828816.8A patent/EP2493442A4/en not_active Ceased
- 2010-10-24 JP JP2012536912A patent/JP2013508457A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231606A (en) * | 1996-08-01 | 1999-10-13 | 史密丝克莱恩比彻姆药品(私人)有限公司 | Composition comprising mupirocin and chlorhexidine |
| US20040185028A1 (en) * | 2003-03-19 | 2004-09-23 | Zhenze Hu | Antimicrobial compositions containing ethanolamine buffer and biguanide disinfectant |
| CN1871039A (en) * | 2003-09-22 | 2006-11-29 | 技术革新公司 | Wound irrigation device and method |
| US20050124946A1 (en) * | 2003-12-05 | 2005-06-09 | Sergio Landau | Wound irrigation apparatus and method |
| US20060051385A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US20070173773A1 (en) * | 2006-01-23 | 2007-07-26 | Keith Stamler | Wound irrigation splashback shield |
| WO2008077114A2 (en) * | 2006-12-19 | 2008-06-26 | Innovation Technologies, Inc. | Devices and methods for delivering active agents to target sites |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105979940A (en) * | 2013-12-12 | 2016-09-28 | 创新技术股份有限公司 | Materials and methods for controlling infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2778081A1 (en) | 2011-05-12 |
| EP2493442A4 (en) | 2013-05-15 |
| WO2011056486A3 (en) | 2011-09-29 |
| JP2013508457A (en) | 2013-03-07 |
| EP2493442A2 (en) | 2012-09-05 |
| WO2011056486A2 (en) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11559503B2 (en) | Materials and methods for controlling infections | |
| Rodeheaver et al. | Wound cleansing, wound irrigation, wound disinfection | |
| US20210154158A1 (en) | Devices, methods, and compositions for controlling infections | |
| CN101594895B (en) | Devices and methods for delivering active agents to target sites | |
| CN102711709A (en) | Devices, methods, and composition for controlling infections | |
| 김신혜 | How clean is the rhinoplasty field? | |
| Paliy et al. | THE EFFICACY OF DECASAN ANTISEPTIC AGENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121003 |